Respiratory Tract Infection Treatment Market - Size, Share, trends, and Forecast, 2022 - 2028

Respiratory tract infection is any infection in the nose, sinuses around the nose, throat (pharynx), voice box (larynx), and windpipe (trachea), airways (bronchi) or lungs, which may occur anytime, usually beginning with cold. This infection is usually caused by bacteria and viruses. Virus prone respiratory tract infection are easily transmitted and very contagious while bacterial infection can also be developed during the course of an upper respiratory tract infection. Respiratory tract infection is generally divided into two categories- upper respiratory tract infection (infection in nose, throat, and pharynx) and lower respiratory tract infection (infection below the larynx).

Market Dynamics

The global respiratory tract infection market is expected to witness lucrative growth due to factors such as increasing prevalence of lung diseases, surge in geriatric population, and rising risk of pneumonia in children. According to the World Health Organization (WHO), respiratory syncytial virus (RSV) is responsible for around 30 million lower respiratory tract infection cases in children worldwide. The prevalence of such viral diseases is expected to drive growth of the global market over the forecast period.

Increasing air pollution can severely affect respiratory health of children as well as adults. Various studies have shown effects of air pollution that can exacerbate existing respiratory conditions such as asthma, COPD, and upper airway allergies.

However, adverse effects of using NSAIDs and antibiotics on patients suffering from respiratory tract infection may hinder growth of the market. In 2015, the U.S. Food and Drug Administration (FDA) increased the warning labels on over-the-counter NSAIDs to highlight elevated risks for heart attack and stroke.

Key features of the study:

This report provides in-depth analysis of the respiratory tract infection treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players

It profiles leading players in the global respiratory tract infection treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Key players covered as a part of this study include Abbott Laboratories, AstraZeneca, Plc, Abbvie Inc., Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, F. Hoffman La Roche Ltd, Sanofi, and Teva Pharmaceutical Industries Ltd.

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics

The global respiratory tract infection treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for respiratory tract infection treatment market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Respiratory Tract Infection Treatment Market, By Drug Class:

Antibiotics

Non-Steroidal Anti-Inflammatory Drug (NSAIDS)

Cough Suppressant

Nasal Decongestant

Others

Global Respiratory Tract Infection Treatment Market, By Disease Indication:

Upper Respiratory Tract Infection

Lower Respiratory Tract Infection

Global Respiratory Tract Infection Treatment Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Respiratory Tract Infection Treatment Market, By Region:

North America

By Country:

U.S.

Canada

By Drug Class:

Antibiotics

Non-Steroidal Anti-Inflammatory Drug (NSAIDS)

Cough Suppressant

Nasal Decongestant

Others

By Disease Indication:

Upper Respiratory Tract Infection

Lower Respiratory Tract Infection

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Europe

By Country:

U.K.

Germany

Italy

Spain

France

Russia

Rest of Europe

By Drug Class:

Antibiotics

Non-Steroidal Anti-Inflammatory Drug (NSAIDS)

Cough Suppressant

Nasal Decongestant

Others

By Disease Indication:

Upper Respiratory Tract Infection

Lower Respiratory Tract Infection

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Asia Pacific

By Country:

Australia

India

China

Japan

ASEAN

South Korea

Rest of Asia Pacific

By Drug Class:

Antibiotics

Non-Steroidal Anti-Inflammatory Drug (NSAIDS)

Cough Suppressant

Nasal Decongestant

Others

By Disease Indication:

Upper Respiratory Tract Infection

Lower Respiratory Tract Infection

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Latin America

By Country:

Brazil

Mexico

Argentina

Rest of Latin America

By Drug Class:

Antibiotics

Non-Steroidal Anti-Inflammatory Drug (NSAIDS)

Cough Suppressant

Nasal Decongestant

Others

By Disease Indication:

Upper Respiratory Tract Infection

Lower Respiratory Tract Infection

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Middle East

By Country:

GCC

Israel

Rest of Middle East

By Drug Class:

Antibiotics

Non-Steroidal Anti-Inflammatory Drug (NSAIDS)

Cough Suppressant

Nasal Decongestant

Others

By Disease Indication:

Upper Respiratory Tract Infection

Lower Respiratory Tract Infection

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Africa

By Country:

South Africa

Central Africa

North Africa

By Drug Class:

Antibiotics

Non-Steroidal Anti-Inflammatory Drug (NSAIDS)

Cough Suppressant

Nasal Decongestant

Others

By Disease Indication:

Upper Respiratory Tract Infection

Lower Respiratory Tract Infection

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Company Profiles

Abbott Laboratories*

Company Overview

Product Portfolio

Financial Performance

Recent Highlights

Strategies

AstraZeneca, Plc

Abbvie Inc.

Boehringer Ingelheim GmbH

Cipla Pharmaceutical Company

GlaxoSmithKline plc

Pfizer Inc.

Merck & Co.

Novartis AG

F. Hoffman La Roche Ltd

Sanofi

Teva Pharmaceutical Industries Ltd.

“*” marked represents similar segmentation in other categories in the respective section.